Product Description
Semaglutide: Advanced GLP-1 Receptor Agonist
A potent and long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, Semaglutide is a cornerstone in the management of type 2 diabetes and chronic weight management. Engineered for sustained action, it offers significant benefits in glycemic control and cardiovascular risk reduction. Its innovative formulation ensures high efficacy and patient compliance, making it a preferred choice in modern therapeutic strategies.
Key Features
- Once-weekly administration for enhanced convenience
- Significant HbA1c reduction in type 2 diabetes patients
- Promotes substantial and sustained weight loss
- Demonstrated cardiovascular benefits, reducing major adverse events
- Improved pancreatic beta-cell function and insulin secretion
- Low risk of hypoglycemia when used as monotherapy
Indications
- Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults.
- Chronic Weight Management: For adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, type 2 diabetes).
Technical Specifications
| Parameter | Specification |
|---|---|
| Mechanism of Action | GLP-1 Receptor Agonist |
| Molecular Formula | C187H291N45O59 |
| Molecular Weight | 4113.58 g/mol |
| Half-life | Approximately 7 days |
| Administration Route | Subcutaneous injection |
| Storage Conditions | Refrigerated (2°C to 8°C), protect from light |
| Purity (HPLC) | >98.0% (typical pharmaceutical grade) |
| Appearance | White to off-white powder |
For detailed technical data sheets, clinical trial results, or partnership inquiries, please contact our sales and technical support team.
